Literature DB >> 18537458

Management of fibromyalgia and comorbid psychiatric disorders.

Lesley M Arnold1.   

Abstract

According to the American College of Rheumatology, fibromyalgia is widespread pain of at least 3 months' duration in combination with pain at 11 or more of 18 specific tender point sites on the body. Many individuals with fibromyalgia also have comorbid psychiatric disorders, which can present diagnostic dilemmas and require additional treatment considerations to optimize patient outcomes. Fibromyalgia has been found to be strongly associated with depressive and anxiety symptoms, a personal or family history of depression, and accompanying antidepressant treatment. Psychiatric comorbidities negatively impact the severity and course of fibromyalgia. Pharmacotherapy can be employed to control fibromyalgia and comorbid mood and anxiety disorders. Additionally, nonpharmacologic therapies for fibromyalgia and comorbid psychiatric disorders include cognitive-behavioral therapy and aerobic exercise. The efficacy of pharmacologic and nonpharmacologic treatments is examined in this article, as well as the diagnostic difficulties that comorbid disorders present.

Entities:  

Mesh:

Year:  2008        PMID: 18537458

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  Is psychological distress intrinsic to fibromyalgia syndrome? Cross-sectional analysis in two clinical presentations.

Authors:  Monika Salgueiro; Zigor Aira; Itsaso Buesa; Juan Bilbao; Jon Jatsu Azkue
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

Review 2.  Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

Authors:  Jair de Jesus Mari; Luís Fernando Tófoli; Cristiano Noto; Li M Li; Alessandra Diehl; Angélica M Claudino; Mario F Juruena
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

3.  Advancing the screening of fibromyalgia in late-life depression: practical implications for psychiatric settings.

Authors:  John R Jochum; Amy E Begley; Mary Amanda Dew; Debra K Weiner; Jordan F Karp
Journal:  Int Psychogeriatr       Date:  2015-04-24       Impact factor: 3.878

Review 4.  Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Authors:  Benji T Kurian; Tracy L Greer; Madhukar H Trivedi
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

5.  Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey.

Authors:  Esme Fuller-Thomson; Jodie Nimigon-Young; Sarah Brennenstuhl
Journal:  Rheumatol Int       Date:  2011-01-08       Impact factor: 2.631

6.  Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin.

Authors:  Philip J Mease; Mildred V Farmer; Robert H Palmer; R Michael Gendreau; Joel M Trugman; Yong Wang
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-06       Impact factor: 5.346

7.  Differential effects of bifrontal and occipital nerve stimulation on pain and fatigue using transcranial direct current stimulation in fibromyalgia patients.

Authors:  Wing Ting To; Evan James; Jan Ost; John Hart; Dirk De Ridder; Sven Vanneste
Journal:  J Neural Transm (Vienna)       Date:  2017-03-20       Impact factor: 3.575

Review 8.  Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine.

Authors:  Afton L Hassett; Richard N Gevirtz
Journal:  Rheum Dis Clin North Am       Date:  2009-05       Impact factor: 2.670

9.  Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families.

Authors:  Laia Rodriguez-Revenga; Irene Madrigal; Javier Pagonabarraga; Mar Xunclà; Celia Badenas; Jaime Kulisevsky; Beatriz Gomez; Montserrat Milà
Journal:  Eur J Hum Genet       Date:  2009-04-15       Impact factor: 4.246

10.  Subgrouping patients with fibromyalgia according to the results of the Fibromyalgia Impact Questionnaire: a replication study.

Authors:  Elena P Calandre; Jocelyne Garcia-Carrillo; Juan M Garcia-Leiva; Fernando Rico-Villademoros; Rocío Molina-Barea; Carmen M Rodriguez-Lopez
Journal:  Rheumatol Int       Date:  2010-05-20       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.